MedTrace Logo

Cambridge Brain Mets Trial 1

NCT02768337 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2024-01-31

No results posted yet for this study

Summary

Proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy.

Conditions

Interventions

DRUG

Afatinib

RADIATION

2 Gy targeted radiotherapy

RADIATION

4 Gy targeted radiotherapy

Sponsors & Collaborators

Principal Investigators

  • Richard Baird, MD PhD · Cambridge University Hospitals NHS Foundation Trust

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-03-10
Primary Completion
2020-08-12
Completion
2021-08-12

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02768337 on ClinicalTrials.gov